TRC102 is intended to reverse resistance to Temodar chemotherapy by targeting a specific DNA repair pathway. The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary anti-tumor activity, of TRC102 in patients with advanced cancer who are also receiving Temodar. TRC102 is also being developed to reverse resistance to the chemotherapeutic Alimta(r), and a second Phase I trial of TRC102 combined with Alimta(r) is expected to begin later in 2008.
Charles Theuer, president and CEO of Tracon, said: “We view TRC102 as a significant first-in-class therapy that targets an important mechanism of chemotherapy resistance.”